Galapagos NV (NASDAQ:GLPG)
| 231.36 Delayed Data As of Jan 24 |  -0.74 / -0.32%Today’s Change | 94.75 Today|||52-Week Range 242.38 | +11.86% Year-to-Date |
Latest GLPG News | Press Releases
| Which Big Biotech Has the Safer Dividend -- Amgen or Gilead Sciences? 7:30am / MotleyFool.com - Paid Partner Content | Better Buy: Vertex Pharmaceuticals vs. Galapagos Jan 25 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 232.10 |
| Today’s open | 237.80 |
| Day’s range | 231.14 - 238.43 |
| Volume | 184,600 |
| Average volume (3 months) | 132,920 |
| Market cap | $14.3B |
Data as of 4:00pm ET, 01/24/2020
Growth & Valuation
| Earnings growth (last year) | +75.16% |
| Earnings growth (this year) | +1,021.35% |
| Earnings growth (next 5 years) | +46.38% |
| Revenue growth (last year) | +135.28% |
| P/E ratio | 42.9 |
| Price/Sales | 14.03 |
| Price/Book | 9.08 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ALNYAlnylam Pharmaceutic... | +2.04 | +1.73% |
| INCYIncyte Corp | -1.50 | -1.92% |
| MYLMylan NV | -0.29 | -1.31% |
| BHCValeant Pharmaceutic... | -0.79 | -2.71% |
Data as of 6:30pm ET, 01/24/2020
Financials
| Next reporting date | February 20, 2020 |
| EPS forecast (this quarter) | $0.04 |
| Annual revenue (last year) | $340.8M |
| Annual profit (last year) | -$34.5M |
| Net profit margin | -10.13% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Mechelen, Brussels Region |
Forecasts
